Poseida Therapeutics to Provide Update on Phase 1 Study of P-BCMA-101 at the 2018 American Society of Hematology Annual Meeting

SAN DIEGO, Nov. 29, 2018 (GLOBE NEWSWIRE) — Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company focused on leveraging proprietary next-generation, non-viral gene engineering technologies to create life-saving therapeutics, today announced that an update from the first five cohorts of an ongoing Phase 1 study of P-BCMA-101, Poseida’s lead autologous CAR-T therapeutic candidate for patients with relapsed/refractory multiple myeloma, will be presented at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego on December 3, 2018.